Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Autoantibodies against advanced glycation endproducts (AGEs) in human serum (CROSBI ID 481350)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Turk, Zdenka ; Benko, Bojan Autoantibodies against advanced glycation endproducts (AGEs) in human serum // Clinical chemistry and laboratory medicine / Şiest, Gerard (ur.). 2001. str. 155-155

Podaci o odgovornosti

Turk, Zdenka ; Benko, Bojan

engleski

Autoantibodies against advanced glycation endproducts (AGEs) in human serum

Incubation of proteins with reducing sugar results in time-related production of advanced glycation endproducts (AGE). AGE modified proteins have antigenic properties. In the present study we develop an immunoenzyme assay for detection of autoantibodies against AGE in human serum. A blocking ELISA was chosen to test immunoreactivity against AGE epitope. Human serum albumin (AGE-HSA) glycated in vitro was used as a solid phase antigen. Multiple immunization of rabbits by AGE-rabbit albumin was used in the preparation of AGE polyclonal antiserum. An excess of AGE-HSA antigen was wall-fixed on the microtiter plate and during incubation with serum, autoantibodies bound to these antigens. This was followed by incubation with rabbit anti-AGE- antibodies to block the rest of free antigens. In parallel, native HSA served as a control antigen to measure non-specific reactions. The binding of autoantibodies against AGE for each serum sample was separately calculated as the percentage inhibition of antibody binding activity with correction for non-specific binding. Competitive ELISA measured total serum AGEs. AGE and anti-AGE antibodies were detected in diabetic (n=63) and control (n=20) serum. Total AGE level was significantly higher in diabetics (13.9 5.7 vs. 8.5 1.0  gEq/ml, p<0.001). We measured a broad range (3.1-87.4) of antibody binding activity in both groups. Unexpectedly, the mean percentage of inhibition measured in the control group (47.3 14.4%) significantly exceeded the values measured in the group of diabetic patients (26.0 11.8%, p<0.001). Thirty-one (48%) diabetic patient showed a mean value for free AGE antibodies lower by 2SD than that in the control subjects and they were considered as antibody negative. The antibody negative patients had a higher level of serum AGE (14.4 6.2 vs. 13.4 6.2, p<0.01). The presented method might be useful in the evaluation of advanced glycation consequences in diabetes and aging.

diabetes; advanced glycation; autoantibodies; immunoassay

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

155-155.

2001.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Clinical chemistry and laboratory medicine

Şiest, Gerard

Berlin: Walter de Gruyter

1434-6621

Podaci o skupu

IFCC-FESCC European Congress of Clinical Chemistry and Laboratory Medicine (14 ; 2001)

poster

26.05.2001-31.05.2001

Prag, Češka Republika

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost